January 25, 2024 10:59 AM EST
News Briefing

Glen­mark, Al­pham­ab deal worth up to $700M; Tour­ma­line’s $150M of­fer­ing; Re­pare records $40M mile­stone

Jaimy Lee

Deputy Editor

Katherine Lewin

News Reporter

Plus, news about Ve­ra Ther­a­peu­tics and Cel­lec­tar Bio­sciences:

Al­pham­ab On­col­o­gy, Glen­mark ink li­cens­ing deal: Per the agree­ment, Glen­mark will spend up …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Up­dat­ed: Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force as CEO de­parts

Post-Hoc: Biose­cure is dead. Long live Biose­cure? 

No­vo Nordisk part­ners with Broad In­sti­tute spin­out Pho­tys af­ter the star­tup's lay­offs

US spent $450B on drugs last year, CMS says, with new obe­si­ty and di­a­betes drugs adding to to­tal

A service from the Financial Times